Select language:

Pluvicto Cost in India
PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is approved to treat adult patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have previously been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Pluvicto Drug in India is a radioactive medication that is injected into a vein. As the drug enters the body, it binds to malignant cells and directs radioactive material to locations where the cancer has spread (metastases). The FDA has currently approved this medicine for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. What Is Pluvicto Treatment? Pluvicto is a radiopharmaceutical (a drug with a trace of radioactivity)…
Read More

    By submitting the form I agree to the Terms and Conditions and Privacy Policy of MedSurge India.

    How Does Pluvicto Work? This Targeted PSMA Treatment in India employs radiation to reduce prostate cancer cells. It contains medication that: Focuses the medicine on tumors, preventing it from damaging other parts of your body. Radiation is used to damage and eliminate cancer cells. Before beginning treatment, you will have…
    Read More
    The Most Important Frequently Asked Questions

    Q: What Is the Duration of the Pluvicto Treatment?

    A: Pluvicto therapy is administered in six sequential infusions. The infusions are scheduled roughly 6 weeks apart. Each infusion will take place in MSK’s main hospital. You will get regular blood tests to monitor your health while your Pluvicto treatment.

    Q: What Is the Best Prostate Cancer Medication?

    A: Bicalutamide, often known as Casodex, is a cancer treatment medication. It is a prostate cancer treatment.

    Q: Who Is a Pluvicto Candidate?

    A: You may be eligible if you have prostate cancer that has gone beyond the prostate and has progressed despite prior treatments (including hormonal therapies and at least one chemotherapy).

    Q: Is It Possible to Treat Prostate Cancer Permanently?

    A: Although there is no cure for benign prostatic hyperplasia (BPH), generally known as an enlarged prostate, there are several effective treatment options. Treatments target prostate development, which causes BPH symptoms. Once prostate development begins, it frequently continues until medical therapy is initiated.

    Q: Who Developed Pluvicto?

    A: Novartis AG (Basel, Switzerland) markets PluvictoTM. PSMA-617 was created by the German Cancer Research Centre and the University Hospital Heidelberg in Heidelberg, Germany.

    Start your Journey to Good Health With Medsurge India

    Trusted by Patients from Across the World

    10,000+ Patients Assisted

    From 50+ Countries

    400+ Top Hospitals and Clinics

    1500+ Specialized Doctors

      By submitting the form I agree to the Terms and Conditions and Privacy Policy of MedSurge India.

      By using our site, you agree to our Terms and Conditions and Privacy Policy. Medsurgeindia does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

      © Copyright 2023 NSM ONLINE SOLUTIONS PRIVATE LIMITED. All rights reserved.

      Made with ♥️ in Bharat
      Enquire Us